These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23091189)

  • 1. Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
    Koyama K; Nakai D; Takahashi M; Nakai N; Kobayashi N; Imai T; Izumi T
    Drug Metab Dispos; 2013 Jan; 41(1):180-7. PubMed ID: 23091189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.
    Yoshihara K; Ishizuka H; Kubo Y
    Drug Metab Pharmacokinet; 2013; 28(5):416-26. PubMed ID: 23574886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
    Koyama K; Takahashi M; Oitate M; Nakai N; Takakusa H; Miura S; Okazaki O
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4845-51. PubMed ID: 19687241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
    Yamashita M
    Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
    Ishizuka H; Toyama K; Yoshiba S; Okabe H; Furuie H
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3873-8. PubMed ID: 22526307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
    Koyama K; Takahashi M; Nakai N; Takakusa H; Murai T; Hoshi M; Yamamura N; Kobayashi N; Okazaki O
    Xenobiotica; 2010 Mar; 40(3):207-16. PubMed ID: 20146556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
    Kubo S; Tokumitsu A; Tomozawa T; Kakuta M; Yamashita M
    J Infect Chemother; 2012 Feb; 18(1):69-74. PubMed ID: 21881920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
    Toyama K; Furuie H; Ishizuka H
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
    Ishizuka H; Yoshiba S; Yoshihara K; Okabe H
    J Clin Pharmacol; 2011 Feb; 51(2):243-51. PubMed ID: 20197485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
    Ishizuka H; Yoshiba S; Okabe H; Yoshihara K
    J Clin Pharmacol; 2010 Nov; 50(11):1319-29. PubMed ID: 20145259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.
    Koyama K; Ogura Y; Nakai D; Watanabe M; Munemasa T; Oofune Y; Kubota K; Shinagawa A; Izumi T
    Drug Metab Dispos; 2014 Jun; 42(6):1031-8. PubMed ID: 24682756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
    Kashiwagi S; Watanabe A; Ikematsu H; Uemori M; Awamura S;
    Clin Infect Dis; 2016 Aug; 63(3):330-7. PubMed ID: 27118785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases.
    Ogawa T; Tanaka K; Ohgino K; Omori N; Betsuyaku T; Sayama K
    J Infect Chemother; 2019 Dec; 25(12):1043-1046. PubMed ID: 31178281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a single inhalation of laninamivir octanoate in children with influenza.
    Katsumi Y; Otabe O; Matsui F; Kidowaki S; Mibayashi A; Tsuma Y; Ito H
    Pediatrics; 2012 Jun; 129(6):e1431-6. PubMed ID: 22614774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
    Panozzo J; Oh DY; Margo K; Morton DA; Piedrafita D; Mosse J; Hurt AC
    Antiviral Res; 2015 Aug; 120():66-71. PubMed ID: 26022199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Niwa S; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    Int J Antimicrob Agents; 2012 Nov; 40(5):381-8. PubMed ID: 22871369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    J Infect Chemother; 2013 Apr; 19(2):223-32. PubMed ID: 23085742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
    Nakano T; Okumura A; Tanabe T; Niwa S; Fukushima M; Yonemochi R; Eda H; Tsutsumi H
    Scand J Infect Dis; 2013 Jun; 45(6):469-77. PubMed ID: 23373850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.